<DOC>
	<DOCNO>NCT02045264</DOCNO>
	<brief_summary>This single-dose study evaluate pharmacokinetics , safety , tolerability icatibant administer adult Japanese subject .</brief_summary>
	<brief_title>Open-label , Single-arm Study Assess Pharmacokinetics , Safety , Tolerability Single Subcutaneous Dose Icatibant Healthy Japanese Volunteers</brief_title>
	<detailed_description>Icatibant study treatment acute attack hereditary angioedema ( HAE ) , autosomal dominant disorder characterize recurrent self-limiting episode edema skin , larynx , gastrointestinal tract . The serious manifestation HAE attack laryngeal edema , cause obstruction upper airway may lead death asphyxiation undiagnosed and/or untreated . Icatibant approve 40 country around world include United States ( US ) Europe treatment acute attack hereditary angioedema ( HAE ) adult . This study conduct evaluate safety tolerability icatibant Japanese population evaluate whether race/ethnicity impact pharmacokinetics icatibant single subcutaneous injection . This open-label , single-arm study enroll least 12 Japanese subject ( order 12 subject complete study ) , age 18-55 year inclusive . All subject receive single subcutaneous injection 30mg icatibant . The study conduct 1 site US . The study consist Screening Period , Treatment Period , Follow-Up Period .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Icatibant</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<mesh_term>Bradykinin</mesh_term>
	<mesh_term>Peripheral Nervous System Agents</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>1 . Healthy male female volunteer , 18 55 year age , inclusive ; healthy status define absence clinically significant finding medical history screen assessment 2 . Japanese ; define born Japan , live outside Japan 10 year , Japanese parent Japanese maternal paternal grandparent 3 . Body mass index 18 28 kg/m2 , inclusive 1 . History , current , clinically significant disease and/or abnormalities 2 . Smoking habit excess 5 cigarette per day equivalent within 30 day Day 1 inability refrain smoking study confinement period 3 . Subject current abnormal thyroid function , define abnormal screening thyroid stimulate hormone ( TSH ) free thyroxine ( T4 ) . Treatment stable dose thyroid medication least 12 week permit 4 . History drug allergy allergy , opinion investigator , contraindicate participation 5 . Male subject consume 21 unit alcohol per week 3 unit per day . Female subject consume 14 unit alcohol per week 2 unit per day . ( 1 alcohol unit =1 beer =1 wine ( 5oz/150mL ) =1 liquor ( 1.5oz/40mL ) =0.75oz alcohol ) 6 . Routine consumption 2 unit caffeine per day subject experience caffeine withdrawal headache . ( 1 caffeine unit contain follow item : one 6oz ( 180mL ) cup coffee , two 12oz ( 360mL ) can cola , one 12oz cup tea , three 1oz ( 85g ) chocolate bar . Decaffeinated coffee , tea , cola consider contain caffeine ) 7 . Current use medication ( include overthecounter , herbal , homeopathic preparation ) exception female hormonal replacement therapy hormonal contraceptive . Occasional use overthecounter dos ibuprofen acetaminophen minor selflimited pain ( eg , headache ) also acceptable . Current use define use within 7 day first dose investigational product\ 8 . Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Firazyr</keyword>
	<keyword>Angioedema</keyword>
	<keyword>Angioedemas , Hereditary</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Urticaria</keyword>
	<keyword>Skin Diseases , Vascular</keyword>
	<keyword>Skin Diseases</keyword>
	<keyword>Hypersensitivity , Immediate</keyword>
	<keyword>Hypersensitivity</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Icatibant</keyword>
	<keyword>Anti-Inflammatory Agents , Non-Steroidal</keyword>
	<keyword>Analgesics , Non-Narcotic</keyword>
	<keyword>Analgesics</keyword>
	<keyword>Sensory System Agents</keyword>
	<keyword>Peripheral Nervous System Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Antirheumatic Agents</keyword>
	<keyword>Adrenergic beta-Antagonists</keyword>
	<keyword>Adrenergic Antagonists</keyword>
	<keyword>Adrenergic Agents</keyword>
	<keyword>Neurotransmitter Agents</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>